Ying Li

18.3k total citations · 10 hit papers
320 papers, 12.5k citations indexed

About

Ying Li is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Ying Li has authored 320 papers receiving a total of 12.5k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Molecular Biology, 70 papers in Immunology and 46 papers in Oncology. Recurrent topics in Ying Li's work include interferon and immune responses (20 papers), Autophagy in Disease and Therapy (20 papers) and Cell death mechanisms and regulation (19 papers). Ying Li is often cited by papers focused on interferon and immune responses (20 papers), Autophagy in Disease and Therapy (20 papers) and Cell death mechanisms and regulation (19 papers). Ying Li collaborates with scholars based in China, United States and Canada. Ying Li's co-authors include Junying Yuan, Yifan Cheng, Melanie D. Ohi, Thomas Walz, Laurence A. Lasky, Donald Dowbenko, Weiqin Jiang, Linfu Zhou, Yuanyuan Zhou and Dana E. Christofferson and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Ying Li

306 papers receiving 12.3k citations

Hit Papers

Beclin1 Controls the Levels of p53 by Regulating the Deu... 2003 2026 2010 2018 2011 2004 2003 2013 2015 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ying Li China 53 6.7k 2.1k 1.7k 1.5k 1.1k 320 12.5k
Walter Malorni Italy 66 6.4k 1.0× 3.4k 1.6× 2.2k 1.3× 1.6k 1.1× 1.0k 0.9× 370 14.9k
Takashi Yamamoto Japan 72 10.9k 1.6× 2.0k 1.0× 1.7k 1.0× 2.0k 1.3× 1.4k 1.3× 689 21.2k
Susan A. Elmore United States 28 6.2k 0.9× 1.8k 0.8× 1.2k 0.7× 1.2k 0.8× 1.3k 1.2× 89 13.0k
Hong Wang China 53 4.6k 0.7× 2.2k 1.1× 765 0.5× 995 0.7× 1.1k 1.0× 344 10.4k
Yasushi Ishihama Japan 61 13.7k 2.0× 1.3k 0.6× 1.4k 0.8× 1.2k 0.8× 1.0k 0.9× 253 21.5k
Stephen W. G. Tait United Kingdom 49 10.0k 1.5× 3.5k 1.7× 3.4k 2.0× 1.9k 1.2× 1.8k 1.6× 87 15.5k
Gregory J. Anderson Australia 74 6.8k 1.0× 1.3k 0.6× 1.5k 0.9× 1.2k 0.8× 1.7k 1.5× 276 21.3k
István Boldogh United States 78 10.4k 1.6× 2.4k 1.2× 2.3k 1.4× 1.8k 1.2× 1.8k 1.6× 304 17.7k
Kym F. Faull United States 65 8.7k 1.3× 1.5k 0.7× 741 0.4× 1.1k 0.7× 759 0.7× 309 17.2k
Philippe Marchetti France 62 9.9k 1.5× 2.3k 1.1× 1.4k 0.8× 2.4k 1.6× 1.6k 1.5× 177 16.1k

Countries citing papers authored by Ying Li

Since Specialization
Citations

This map shows the geographic impact of Ying Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Li more than expected).

Fields of papers citing papers by Ying Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Li. The network helps show where Ying Li may publish in the future.

Co-authorship network of co-authors of Ying Li

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Li. A scholar is included among the top collaborators of Ying Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Li. Ying Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Ying, et al.. (2025). An Intranasal Nanomedicine Functions as Both Potent Broad‐spectrum Viral Inhibitor and Quasi‐Vaccine. Advanced Functional Materials. 35(28). 1 indexed citations
2.
Jia, Yan, Ling Li, Ying Li, et al.. (2025). Iron overload mediates cytarabine resistance in AML by inhibiting the TP53 signaling pathway. Acta Biochimica et Biophysica Sinica. 57(4). 646–655.
3.
Zhou, Yuzheng, Taijie Guo, Xiao Zhang, et al.. (2025). Discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model. Acta Pharmaceutica Sinica B. 16(1). 387–405.
6.
Li, Ying, et al.. (2024). Effectiveness and safety of enzyme replacement therapy in the treatment of Fabry disease: a Chinese monocentric real-world study. Orphanet Journal of Rare Diseases. 19(1). 422–422. 2 indexed citations
7.
Qi, Xiaoliang, XinXin Ge, Xiaojing Chen, et al.. (2024). An Immunoregulation Hydrogel with Controlled Hyperthermia‐Augmented Oxygenation and ROS Scavenging for Treating Diabetic Foot Ulcers. Advanced Functional Materials. 34(33). 100 indexed citations breakdown →
8.
Zhou, Xingyu, Jun Zhang, Ying Li, et al.. (2024). Advanced oxidation protein products attenuate the autophagy-lysosome pathway in ovarian granulosa cells by modulating the ROS-dependent mTOR-TFEB pathway. Cell Death and Disease. 15(2). 161–161. 14 indexed citations
9.
Xia, Min, Xingxing Xie, Weimin Sun, et al.. (2024). RIPK1 activation in Mecp2-deficient microglia promotes inflammation and glutamate release in RTT. Proceedings of the National Academy of Sciences. 121(6). e2320383121–e2320383121. 11 indexed citations
10.
Liu, Chang, et al.. (2023). Unravelling potential biomarkers for acute and chronic brucellosis through proteomic and bioinformatic approaches. Frontiers in Cellular and Infection Microbiology. 13. 1216176–1216176. 7 indexed citations
11.
Xu, Lingzhi, Fangyu Li, Meina Quan, et al.. (2023). Upregulation of Wnt2b exerts neuroprotective effect by alleviating mitochondrial dysfunction in Alzheimer's disease. CNS Neuroscience & Therapeutics. 29(7). 1805–1816. 10 indexed citations
12.
Cheng, Yan, Lin Cheng, Ying Qin, et al.. (2023). Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads. Journal of Medicinal Chemistry. 66(4). 2608–2621. 10 indexed citations
13.
Li, Yanhua, Shitong Qiao, Rong Zhang, et al.. (2023). Antibody response assessment of immediate breakthrough infections after zero-COVID policy adjustment in China. The Lancet Regional Health - Western Pacific. 40. 100945–100945. 5 indexed citations
14.
Cheng, Lin, Kaixuan Shi, Yan Cheng, et al.. (2022). Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer. Cancer Research. 82(19). 3588–3602. 25 indexed citations
15.
Li, Shulin, Rui Yan, Jialu Xu, et al.. (2021). A new type of ERGIC–ERES membrane contact mediated by TMED9 and SEC12 is required for autophagosome biogenesis. Cell Research. 32(2). 119–138. 59 indexed citations
16.
Wang, Rui, Ying Li, Ping Gong, et al.. (2018). Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells. Molecular Cancer Therapeutics. 17(9). 1871–1880. 24 indexed citations
17.
Meng, Huyan, Zhen Liu, Xingyan Li, et al.. (2018). Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis. Proceedings of the National Academy of Sciences. 115(9). E2001–E2009. 109 indexed citations
18.
Huang, Wenmao, Meng Qin, Ying Li, Yi Cao, & Wei Wang. (2017). Dimerization of Cell-Adhesion Molecules Can Increase Their Binding Strength. Langmuir. 33(6). 1398–1404. 3 indexed citations
19.
Keller, Ulrich auf dem, Caroline L. Bellac, Ying Li, et al.. (2010). Novel Matrix Metalloproteinase Inhibitor [18F]Marimastat-Aryltrifluoroborate as a Probe for In vivo Positron Emission Tomography Imaging in Cancer. Cancer Research. 70(19). 7562–7569. 69 indexed citations
20.
Xu, Dongbin, et al.. (2005). The CARD-carrying caspase Dronc is essential for most, but not all,developmental cell death in Drosophila. Development. 132(9). 2125–2134. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026